Buy 5F-MDA-19 Online
5F MDA 19 (5 fluoropentyl MDA 19, 5 fluoro BZO POXIZID, BZO HEXOXIZID analogue) from Davechemicals.com is a high purity synthetic cannabinoid research material supplied strictly for laboratory use only, not for human or veterinary consumption. It is part of the broader MDA 19 CB2 agonist family, valued by serious researchers studying cannabinoid receptor pharmacology, analytical toxicology and seized material profiling across the United Kingdom, United States, Germany, Australia and Asia. Buy 5F-MDA-19 Online
What is 5F MDA 19 5 fluoropentyl MDA 19 (BZO HEXOXIZID analogue) ❓
5F MDA 19, often referred to as 5 fluoropentyl MDA 19 or 5 fluoro BZO POXIZID, is a synthetic cannabinoid that belongs to the MDA 19 OXIZID family, a group of ligands designed to interact primarily with cannabinoid receptors, especially CB2. The parent compound MDA 19 (BZO HEXOXIZID) was initially explored as a CB2 selective agonist for neuropathic pain research, with data showing potent binding at CB2 and relatively lower affinity for CB1 compared with earlier synthetic cannabinoids.
According to open literature and forensic reports, 5F MDA 19 is the 5 fluoropentyl analogue of MDA 19, identified in synthetic smoke blends and seized materials as part of the newer OXIZID generation of cannabinoids. Databases and monographs from groups such as the Center for Forensic Science Research and Education and international bodies like UNODC describe 5F BZO POXIZID as an MDA 19 analogue with a fluorinated pentyl side chain, detected in real world casework from 2021 onwards.
All 5F MDA 19 materials offered on the Davechemicals.com are supplied strictly for research purposes, not for human use, ingestion or any form of in vivo administration.
Why 5F MDA 19 CB2 agonist research matters for serious labs
The original MDA 19 CB2 agonist was studied for neuropathic pain models because CB2 biased ligands can modulate inflammatory and immune related pathways with potentially reduced classic CB1 psychoactivity in animals, although translation to humans is not straightforward. A recent pharmacological evaluation of newer OXIZID synthetic cannabinoids found that MDA 19 produced partial CB1 and CB2 receptor activation in vitro, with an activity profile that resembled THC at certain doses, yet also showed strong rate suppression and variable behavioural effects at higher doses in animals.
For forensic and analytical labs in the UK, USA, Germany, Australia and Asia, 5F MDA 19 and related analogues present three main challenges.
- Identification in seized herbal blends and liquids.
- Limited historic toxicological data, which increases uncertainty.
- Rapid emergence of multiple MDA 19 analogues, including pentyl, 5 fluoropentyl and cyclohexylmethyl versions.
Because of that, many laboratories now build targeted LC MS and GC MS methods around MDA 19 and 5F MDA 19 reference standards, often alongside other cannabinoids sourced from specialist vendors such as Cayman Chemical and informed by NPS monitoring projects and open references.

5F MDA 19 5 fluoropentyl MDA 19 structure and pharmacology
Sources such as Wikipedia and NPS alerts describe MDA 19 and its 5 fluoropentyl analogue as indolinone based synthetic cannabinoids that bind to CB1 and CB2 receptors. The 5 fluoropentyl chain in 5F MDA 19 is structurally analogous to the fluorinated side chains found in earlier synthetic cannabinoids, a modification that has often increased potency at CB1 and CB2 receptors and raised concern in toxicology.
Key points taken from public data on the MDA 19 family.
- MDA 19 shows Ki values in the low nanomolar range at human CB2 receptors and somewhat weaker affinity at CB1, with species differences between rat and human receptors.
- MDA 19 behaves as a CB1 and CB2 agonist in humans, while acting as an inverse agonist at rat CB2 receptors, which underlines how preclinical species data can be misleading if assumed to translate directly.
- 5F analogues such as 5F MDA 19 5 fluoropentyl MDA 19 are flagged by forensic groups as “new generation synthetic cannabinoids”, associated with psychoactive effects and adverse events when used outside controlled research environments.
According to a recent paper on OXIZID cannabinoids, MDA 19 at higher doses in mice caused strong reductions in response rates and variable behaviour, highlighting that “CB2 selectivity” in binding studies does not automatically mean a gentle or predictable clinical profile.
Buy 5F MDA 19 online for laboratory research only
At Davechemicals.com, our buy 5F MDA 19 online listing is aimed at accredited laboratories and experienced researchers who need a consistent 5F MDA 19 (5 fluoropentyl MDA 19) reference standard.
The product is clearly labelled as for research purposes only and shipped only to verified institutional or professional clients, not to casual buyers or individuals seeking personal use.
Our 5F MDA 19 offer is positioned alongside other synthetic cannabinoids such as 5F MDMB, 5F SGT 151, JWH 122 , JWH 210 cannabinoid and EG 018, giving forensic and toxicology teams the option to build a broad cannabinoid panel from a single supplier.
Researchers who also work across dissociatives, stimulants and tryptamines can expand their catalogue with materials like buy 3 MeO PCP online, buy 2 FDCK online USA, buy 5 MeO DMT online or more classical entactogens such as methylone, again strictly for research.
If you need tailored support, batch documentation or region specific shipping advice, you can contact the team via the Davechemicals.com contact to discuss 5F MDA 19 availability for the UK, USA, Germany, Australia or Asia.
Table 1, 5F MDA 19 vs parent MDA 19 vs 5F MDMB 2201
Profile overview of key synthetic cannabinoids for research
| Feature | 5F MDA 19 (5F BZO POXIZID) | MDA 19 (BZO HEXOXIZID) | 5F MDMB 2201 |
|---|---|---|---|
| Core scaffold | Indolinone OXIZID family | Indolinone OXIZID family | Indazole 3 carboxamide |
| Side chain | 5 fluoropentyl | Hexyl | 5 fluoropentyl tert leucinate |
| Intended target in early research | CB2 biased agonist analogue | CB2 selective agonist, neuropathic pain models | Potent CB1 CB2 agonist in early synthetic cannabinoid waves |
| Detection context | Identified in synthetic smoke blends and seized samples | Identified in seized synthetic blends and research lists | Widely detected in NPS casework and toxicology |
| Expected risk if misused | High, limited human data, potential for severe adverse effects | High, psychoactive potential despite CB2 focus | Very high, associated with serious intoxications |
| Research use | Reference standard for analytical methods, receptor and metabolism work | CB2 pharmacology, SAR, analytical standards | Toxicology, seizure profiling, method validation |

